



September 16, 2015

Mirna Therapeutics Announces the Appointment of Alan Fuhrman as Chief Financial Officer

AUSTIN, TX--(Marketwired - September 16, 2015) - Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Alan Fuhrman as Chief Financial Officer (CFO).

Mr. Fuhrman joins Mirna with over 20 years of executive leadership experience in the life sciences and technology industries. He was most recently the CFO of Ambit Biosciences, where he helped lead the company through its initial public offering, and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Mr. Fuhrman currently serves on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand.

"We are excited to welcome Alan to our executive team," said Paul Lammers, M.D., M.Sc., Mirna's President and Chief Executive Officer. "His strong leadership skills and extensive experience driving business-critical financial operations and investor relations functions will be instrumental as we grow our business and advance our pipeline of microRNA-based oncology therapeutics."

Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.

About Mirna Therapeutics, Inc.

Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The company was founded in 2007 and is located in Austin, Texas.

For more information, visit www.mirnarx.com.

Contact Information

Contacts:

Investors

The Trout Group

Josh Barer

646-378-2948

jbarer@troutgroup.com

Media

BMC Communications

Amy Bonanno

646-513-3117

abonanno@bmccommunications.com